News

REGiMMUNE Completes $6 Million Series E Financing

REGiMMUNE Completes $6 Million Series E Financing Tokyo, Japan – April 7, 2017 – REGiMMUNE Corporation announced the closing of a Series E financing on April 7th. The company raised 6 million US in this new round, which was led by SMBC Venture Capital Co., Ltd., the VC …

Moving Headquarters Location

We are proud to announce that we have moved our business to a new location. Our new address is as follows. 35-3 Nihonbashi Hakozaki-cho BRICK GATE 5F Chuou-ku Tokyo 103-0015 Japan.Our Telephone numbers remain the same.

REGiMMUNE Appoints Kenzo Kosuda as Chief Executive Officer

Tokyo Japan — July 1, 2016 — REGiMMMUNE today announced that its Board of Directors has appointed Kenzo Kosuda as Chief Executive Officer effective July 1, 2016. Yasuyuki Ishii will assume the role of Executive Chairman on July 1, 2016, and will continue to serve as the …

REGiMMUNE appoints new board members

REGiMMUNE Corporation (RGI) Appointed  Joseph “Joe” McCracken as a board Tokyo, Japan., Dec 25, 2015 – REGiMMUNE Corporation (RGI) today announced that the Company has appointed Joseph McCracken to its Board of Directors. Dr. McCracken currently advises biopharmaceutica …

Relocation of US Office to Berkeley

REGiMMUNE Corporation relocated its US offices from San Francisco to Berkeley, California. please see access page for the new address.

Moving Headquarters Location

We are proud to announce that we have moved our business to a new location with a much larger working space. Our new address is as follows. 14-9 Nihonbashi Kodenma-cho Fine Bldg. 7F Chuou-ku Tokyo 103-0001 Japan.Our Telephone numbers remain the same.

REGiMMUNE Completes $9.2 Million Series D Financing

REGiMMUNE Completes $9.2 Million Series D Financing Tokyo, Japan – February 14, 2014 – REGiMMUNE Corporation announced the closing of a Series D financing earlier this month. The company raised $9.2 million US in this new round, which was led by Japan Asia Investment Co …

REGiMMUNE appoints new board members

Santa Clara, CA and TOKYO — April 12, 2013 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has appointed Mr. Nakamura, Dr. Misawa, Dr. Matsuishi and Mr.Hirai the as non-executive director. Mr. Nakamura is currently the head …

RGI-2001 was granted Orphan Drug Designation from FDA

RGI-2001 has been granted Orphan Drug Designation for RGI-2001 from FDA Tokyo, Japan-(OCT. 28, 2012) – REGiMMUNE Corporation announced today that RGI-2001, the company’s liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food � …

REGiMMUNE Appoints a new board member

REGiMMUNE Corporation announced today that it has appointed Mr. Kohtaro Toda as a board member. He is currently an investment manager of Japan Asia Investment Co., Ltd. (JAIC), a Japanese venture capital firm with $1 billion under management. The addition of this new ma …

reVax patent has been granted

Basis patent for the target specific tolerance induction by GalCer liposome, reVax technology, has been granted Tokyo, JAPAN–(Nov 28, 2011) – REGiMMUNE Corp. (“Company”) announces that the Japanese Patent Office has granted a patent, containing c …

Publication of GvHD paper

REGiMMUNE Corp. Announces Publication of preclinical GvHD data Tokyo, JAPAN–(Nov 22, 2010) – REGiMMUNE Corp. (“Company”) is pleased to announce the acceptance and publication of the paper entitled “Pharmacological Expansion of Donor-derived …

Astellas and REGiMMUNE to Collaborate on New Vaccine Technology

Tokyo, Japan and Mountain View, CA – July 22, 2009 – REGiMMUNE Corporation today announced that Astellas Pharma Inc. and REGiMMUNE have entered into a collaboration agreement to jointly research and develop a novel vaccine-platform technology. The partnership will combi …

REGiMMUNE to Present at the 50th ASH Annual Meeting

Mountain View, CA – December 5, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company’s potential therapeutic treatment for Graft versus …

Relocation of Headquarters in Japan

Japan headquarters has been relocated to following address as of August 1st 2008. 1-7-8 Kaigan Tokyo Industrial Trade Center 607 (6th Floor) Minato-ku Tokyo 105-0022 JAPAN for detailed direction, please see accesss page

REGiMMUNE Raises $8,000,000 in Series B Financing

Mountain View, CA and TOKYO – May 6, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced today that it has closed its Series B financing for a total of $8 million U.S. Proceeds from the financing will be used to advance the company’s lead …

REGiMMUNE Closes First Tranche of Series B Financing

Mountain View, CA and TOKYO – Feb 1, 2008 – REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has raised a total of $6 million U.S. in a Series B venture capital financing from new and existing investors. The original lead inves …

REGiMMUNE Licensed Immunoregulatory Compound from KIRIN Pharma

MOUNTAIN VIEW, CA and TOKYO – Jan 28, 2008 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that the company recently signed a license agreement with Kirin Pharma Company, Limited for the exclusive worldwide rights to use Kirin …

Robert NEGRIN, M.D. appointed to Scientific and Clinical Advisor

REGiMMUNE today announces it has appointed Dr. Professor Robert NEGRIN as a new Scientific and Clinical Adviser to the company. Dr. Negrin is Professor of Medicine in the Division of Blood and Marrow Transplantation at Stanford University. He also holds the positions of …

REGiMMUNE Receives Grant Award from METI

Mountain View, Calif. and Tokyo, Japan – August 7, 2007 – REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today it has been awarded a grant from the Japanese Ministry of Economy, Trade and Industry (METI). REGiMMUNE received the grant under …

REGiMMUNE established broad collaboration with RIKEN

REGiMMUNE Establishes Broad Collaboration with RIKEN MOUNTAIN VIEW, CA and TOKYO — Mar 22, 2007 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has enter into an Intellectual Property and Industry-Academia Collab …

REGiMMUNE Announces Series A Financing

MOUNTAIN VIEW, CA and TOKYO–Feb 21, 2007 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has raised $4.2 million U.S. in a Series A venture capital financing from new and existing investors. The original lead inv …

Relocation of US Office

Mountain View, CA and Tokyo, Japan — February 1, 2007 — REGiMMUNE Corporation, a privately held biopharmaceutical company, announced today the relocation of its US offices from San Jose to Mountain View, California.

REGiMMUNE Announces Appointment to the Board

Tokyo, Japan – Nov. 29, 2006 – REGiMMUNE Corporation announced today the appointment of Mr. Hiroki NARITA, the Deputy General Manager, Investment Group, NIF SMBC Ventures, Japan, to its Board of Directors. Mr. Narita has participated in the investment of approximately $ …

REGiMMUNE Opens a New Subsidiary in US West Coast.

Tokyo, Japan – Nov. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced the opening of a new subsidiary in the United States in San Jose, California. “REGiMMUNE is planning to enter clinical studies in the US in 2009, for autoimm …

REGiMMUNE Announces Appointments to Scientific Advisory Board

Tokyo, Japan, – Sept. 20, 2006 – REGiMMUNE Corporation announced today the appointment of Dr. Yasuyuki ISHII, Team Leader of the Laboratory for Vaccine Design at the RIKEN Research Center for Allergy and Immunology (RCAI), “We are delighted to have a world-renowne …

Entered into a License Agreement with RIKEN

Tokyo, Japan –Sep. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced that it has entered into a license agreement with RIKEN. Under the agreement, an exclusive right to market/sublicense pharmaceutical products based on RIKEN’s …

Relocated Headquarters

Tokyo, Japan – Sept. 1, 2006 – REGiMMUNE Corporation has relocated its headquarters from Toranomon, Tokyo to: 3-12-5 Shibaura, Ishizaka Bldg. 6F Minato-ku, Tokyo 108-0023 Japan phone +81-3-3456-0820

Completed Seed Round Financing

Tokyo, Japan –Aug. 15, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced the closing of the Company’s Seed Round Financing, adding $1.6 million in additional new equity. New venture capital investors NIF SMBC Ventures, Nikko AntFa …